Emcure Pharmaceuticals Stock Hits Record High Following Strong Quarterly Financial Results
Emcure Pharmaceuticals shares reached a record high after jumping sixteen percent over two sessions following robust Q2FY27 financial results. Profit increased by twenty-nine percent while revenue grew by twenty-four percent. Brokerage firms Jefferies and Kotak maintained buy ratings with target prices of twenty-five hundred rupees and twenty-four hundred fifty rupees.
Effective Not specified in the update
For professionals: Advise clients to review the complete Q2FY27 financial disclosures and balance sheet health · Note that major financial institutions Jefferies and Kotak maintained buy ratings with respective share price targets of twenty-five hundred rupees and twenty-four hundred fifty rupees
Open for the full story →